Download App

Log in to access Online Inquiry
Company Overview More
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
CEO: Schleifer M.D., Ph.D., Leonard S.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

REGN Regeneron Pharmaceuticals
687.695+1.675+0.24%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
101.23% 7.05B 58.76% 5.69B 86.43% 12.53B 91.27% 5.79B
-Cash and cash equivalents
132.68% 3.35B 31.54% 2.89B -- -- 118.21% 3.43B
-Short-term investments
79.34% 3.7B 101.61% 2.81B -- -- 62.1% 2.36B
Receivables
15.96% 4.84B 46.71% 6.04B 46.71% 6.04B 34.97% 5.45B
-Accounts receivable
15.96% 4.84B 71.68% 6.04B 46.71% 6.04B 53.43% 5.45B
Inventory
-8% 1.99B 1.81% 1.95B 1.81% 1.95B 14% 2.05B
Prepaid assets
98.92% 424.9M 106.72% 332.4M -- -- 109.02% 482M
Total current assets
42.28% 14.31B 43.31% 14.01B 60.9% 20.52B 51.42% 13.78B
Non current assets
Net PPE
9.01% 3.56B 8.09% 3.48B 8.09% 3.48B 8.2% 3.4B
-Gross PPE
-- -- 12.12% 4.88B -- -- -- --
-Accumulated depreciation
-- -- -23.61% -1.4B -- -- -- --
Investments and advances
99.9% 7.08B 118.08% 6.84B -- -- 95.86% 5.63B
Non current deferred assets
49.04% 1.14B 2.1% 876.9M 2.1% 876.9M -10.07% 723.2M
Other non current assets
79.82% 262M 32.54% 222.8M 68.81% 555.2M -13.57% 145.9M
Total non current assets
56.05% 12.04B 54.65% 11.42B 11.45% 4.91B 41.65% 9.9B
Total assets
48.26% 26.35B 48.19% 25.43B 48.19% 25.43B 47.17% 23.67B
Liabilities
Current liabilities
Payables
-13.37% 470.3M 137.92% 1.18B -- -- -3.63% 427M
-accounts payable
-13.37% 470.3M 18.61% 564M -- -- -3.63% 427M
-Total tax payable
-- -- 1573.33% 326.3M -- -- -- --
-Due to related parties current
-- -- -- 287.4M -- -- -- --
Current accrued expenses
37.11% 2.05B 6.04% 1.59B -- -- 58.17% 2.06B
Current debt and capital lease obligation
-- -- -- 719.7M -- -- -- 719M
-Current capital lease obligation
-- 0 -- 719.7M -- -- -- 719M
Current deferred liabilities
5.68% 491.3M -23.49% 442M -- -- 2.63% 507.8M
Current liabilities
-6.53% 3.01B 45.79% 3.93B 22.95% 3.45B 58.9% 3.71B
Non current liabilities
Long term debt and capital lease obligation
36.46% 2.7B -26.55% 1.98B 0.15% 2.7B -26.54% 1.98B
-Long term debt
0.08% 1.98B 0.08% 1.98B 0.08% 1.98B 0.07% 1.98B
-Long term capital lease obligation
-- 720M -- 0 0.35% 719.7M -- 0
Non current deferred liabilities
24.07% 33.5M 26.82% 73.3M -18.91% 515.3M -46.14% 56.5M
Other non current liabilities
21.17% 692.5M -1% 680.2M -- -- -19.29% 662.6M
Total non current liabilities
32.94% 3.43B -20.55% 2.73B -3.49% 3.22B -25.46% 2.7B
Total liabilities
11.02% 6.43B 8.6% 6.67B 8.6% 6.67B 7.64% 6.41B
Shareholders'equity
Share capital
0% 100K 0% 100K -- -- 0% 100K
-common stock
0% 100K 0% 100K -- -- 0% 100K
-Preferred stock
-- 0 -- 0 -- -- -- 0
Retained earnings
66.07% 19.94B 74.13% 18.97B -- -- 71.79% 16.74B
Paid-in capital
27.1% 8.75B 20.42% 8.09B -- -- 20.12% 7.92B
Less: Treasury stock
24.16% 8.61B 24.91% 8.26B -- -- 18.72% 7.41B
Gains losses not affecting retained earnings
-1150% -170.1M -189.42% -26.2M -- -- -69.16% 9.5M
Total stockholders'equity
66.27% 19.91B 70.23% 18.77B 70.23% 18.77B 70.44% 17.26B
Total equity
66.27% 19.91B 70.23% 18.77B 70.23% 18.77B 70.44% 17.26B
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%